HUMA (Humacyte) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


HUMA Humacyte Inc HUMA
21 GF Score
Price $0.64
! 6 Warning Signs
View Full Analysis

What is Humacyte Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Humacyte's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HUMA vs ZNTL, AVXL, ELDN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Humacyte's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humacyte Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Humacyte's Margin of Safety % (DCF Earnings Based) falls into.


HUMA
21GF Score
Humacyte Inc HUMA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Humacyte Business Description

Address 2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
21GF Score

Get the complete analysis for HUMA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price